Literature DB >> 17712836

New players in the cytokine orchestra of inflammatory bowel disease.

Massimo C Fantini1, Giovanni Monteleone, Thomas T Macdonald.   

Abstract

In both Crohn's disease (CD) and ulcerative colitis, the pathologic process is almost certainly driven by an aberrant local immune response directed against normal components of the bacterial microflora. Mucosal immune cells interact with nonimmune cells such as epithelial cells and fibroblasts to promote tissue damage; cytokines are essential mediators of this cross talk. Accumulating evidence now suggests that interleukin-21 (IL-21), the newest member of the common gamma-chain-dependent cytokine family, is a key component of the inflammatory cascade. IL-21 is highly produced by activated CD4+ lymphocytes in the inflamed gut of patients with CD, where it contributes to sustaining the ongoing Th1 inflammation. IL-21 also increases the secretion of extracellular matrix-degrading enzymes by fibroblasts and of MIP-3alpha by epithelial cells. Two other cytokines, IL-27 and IL-32, may also be important in the inflammatory pathways that operate in IBD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712836     DOI: 10.1002/ibd.20212

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  23 in total

Review 1.  Gatekeepers of intestinal inflammation.

Authors:  Heather A Arnett; Joanne L Viney
Journal:  Inflamm Res       Date:  2010-01       Impact factor: 4.575

Review 2.  Interleukin-21 triggers effector cell responses in the gut.

Authors:  Daniela De Nitto; Massimiliano Sarra; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

Review 3.  Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.

Authors:  Guillaume Bouguen; Jean-Baptiste Chevaux; Laurent Peyrin-Biroulet
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

4.  Caloric restriction modifies both innate and adaptive immunity in the mouse small intestine.

Authors:  María Antonieta Suárez-Souto; Eleazar Lara-Padilla; Humberto Reyna-Garfias; María Viloria; Pedro López-Sánchez; Víctor Rivera-Aguilar; Ángel Miliar-García; Alexander Kormanovski; María Lilia Domínguez-López; Rafael Campos-Rodríguez
Journal:  J Physiol Biochem       Date:  2011-11-16       Impact factor: 4.158

Review 5.  Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors?

Authors:  Franco Scaldaferri; Carmen Correale; Antonio Gasbarrini; Silvio Danese
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

Review 6.  Role of cytokines in inflammatory bowel disease.

Authors:  Fausto Sanchez-Munoz; Aaron Dominguez-Lopez; Jesus-K Yamamoto-Furusho
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

7.  Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis.

Authors:  Ghada Alsaleh; Laetitia Sparsa; Emmanuel Chatelus; Mathieu Ehlinger; Jacques-Eric Gottenberg; Dominique Wachsmann; Jean Sibilia
Journal:  Arthritis Res Ther       Date:  2010-07-08       Impact factor: 5.156

8.  Cancer antigen 125 levels in inflammatory bowel diseases.

Authors:  Hilmi Ataseven; Zeynel Abidin Oztürk; Mehmet Arhan; Osman Yüksel; Seyfettin Köklü; Mehmet Ibiş; Omer Başar; Fatma Meriç Yilmaz; Ilhami Yüksel
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

9.  Cytokine Patterns in Healthy Adolescent Girls: Heterogeneity Captured by Variable and Person-Centered Statistical Strategies.

Authors:  Lorah D Dorn; Jochebed G Gayles; Christopher G Engeland; Renate Houts; Giovanni Cizza; Lee A Denson
Journal:  Psychosom Med       Date:  2016 Jul-Aug       Impact factor: 4.312

Review 10.  Mucosal cytokine network in inflammatory bowel disease.

Authors:  Akira Andoh; Yuhki Yagi; Makoto Shioya; Atsushi Nishida; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.